Standard BioTools Inc. announced that their Chief Commercial Officer, Jeremy Davis, will step down from his position effective February 1, 2025. The company will enter into a severance agreement ...
Standard BioTools (LAB) expects fourth quarter 2024 revenue of approximately $46.5M and full year 2024 revenue of approximately $174M. “The team worked hard in a difficult environment to deliver ...
Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a ...
Investing.com -- Shares of Standard BioTools Inc. (NASDAQ: LAB) surged 30% following the company's announcement of preliminary fourth quarter revenue that exceeded market expectations. The life ...
On Monday, shares of Standard BioTools saw a significant surge of 26% following the announcement of their preliminary fourth-quarter revenue. The company that merged with SomaLogic in the previous ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...
Investing.com -- Shares of Standard BioTools Inc. (NASDAQ: LAB) surged 30% following the company's announcement of preliminary fourth quarter revenue that exceeded market expectations. The life ...
On Monday, shares of Standard BioTools saw a significant surge of 26% following the announcement of their preliminary fourth-quarter revenue. The company that merged with SomaLogic in the previous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback